Researchers from the UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million grant from the National Institutes of Health to develop advanced imaging and surgical strategies aimed at improving outcomes for patients with glioblastoma, a fast-growing and aggressive brain tumor.

The COVID-19 pandemic did not push nurses out of hospitals or other care settings as feared, but nurses left their primary jobs at nearly double the rate from 2018 to 2022, a new University of Michigan study found. 

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq^®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The application is supported by findings from the phase III Alliance ATOMIC (A021502) trial, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, and the German group Arbeitsgemeinschaft Internistische Onkologie (AIO). The study demonstrated that patients experienced significantly improved outcomes when atezolizumab was added to standard chemotherapy following surgery.

Critical Path Institute today announced the appointment of Milad Alucozai, DrPH, MPH, M.Sc., to its Board of Directors. Dr. Alucozai is a longtime leader in the U.S. biotechnology and startup community who has worked as a founder, investor, operator, and community builder, and is the creator of the Bio-Industrial Technology Stack framework, which reframes biology as a geopolitical and industrial asset. A neuroscientist and startup investor, he bridges computational biology, machine learning, and AI-driven drug development. His appointment reflects the organization’s commitment to integrating emerging biotechnology and human-relevant research models into its global mission of accelerating safer, more effective treatments. 

A study led by researchers at UC Riverside, the University of Connecticut, Brown University, UCLA, and Fordham University highlights the importance of rigorous participant verification procedures in online health research, particularly when studies recruit hardly reached populations and offer compensation for participation.